Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT01439854
Status
Completed

Conditions

  • Insulin Sensitivity
  • Multiple Mitochondrial Dysfunctions Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Treatment arm, 10 mg per day for 2 weeks
  • Placebo — DRUG
    Patients are treated with placebo

Study Details

The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a potent, highly specific inhibitor of renal glucose transport \[SGLT2\].

Key Dates

Start date
Mar 31, 2011
Status verified
Jun 2025
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018

Study Design

Enrollment
18 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo
    this arm is control
  • Experimental: Dapagliflozin
    Interventional arm

Primary Outcome Measure

Change in Insulin Sensitivity [ Time Frame: baseline, two weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Diabetes Division, UTHSCSASan AntonioTexas78229-

Find similar trials in San Antonio, TX

By research site
Diabetes Division, UTHSCSA· San Antonio, TX

Related Studies